Ghatalia, P., Ross, E. A., Zibelman, M. R., Anari, F., Abbosh, P., Tester, W. J., Rose, T. L., Cole, S., Mark, J. R., Viterbo, R., Jerome, E., Horwitz, E. M., Hallman, M. A., Correa, A. F., Smaldone, M. C., Uzzo, R., Chen, D. Y., Kutikov, A., Plimack, E. R., Geynisman, D. M. (2025). A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.815